Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1

Biomedicine and Pharmacotherapy

Volumn 64, Issue 10, 2010, Pages 723-732

  Passic, Shendra R ^a   Ferguson, Mary Lee ^a   Catalone, Bradley J ^b   Kish Catalone, Tina ^a   Kholodovych, Vladyslav ^c   Zhu, Wei ^c   Welsh, William ^c   Rando, Robert ^d   Howett, Mary K ^e   Wigdahl, Brian ^a   Labib, Mohamed ^d   Krebs, Fred C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Novaflux Biosciences Inc   (United States)

^e DREXEL UNIVERSITY   (United States)

Author keywords

Antiviral; Biguanide; HIV 1

Indexed keywords

BIGUANIDE DERIVATIVE; CD45 ANTIGEN; POLYBIGUANIDE DERIVATIVE; POLYETHYLENE HEXAMETHYLENE BIGUANIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PURIFICATION; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; BIGUANIDES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; MICE; MODELS, ANIMAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; POLYETHYLENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649825673     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.10.001     Document Type: Article

References (31)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS epidemic update: November 2009. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2009.
2. Buckheit R.W., Watson K.M., Morrow K.M., Ham A.S. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res 2010, 85:142-158.
3. Garg A.B., Nuttall J., Romano J. The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother 2009, 19:143-150.
4. Minces L.R., McGowan I. Advances in the development of microbicides for the prevention of HIV infection. Curr Infect Dis Rep 2010, 12:56-62.
5. Larsen B. Vaginal flora in health and disease. Clin Obstet Gynecol 1993, 36:107-121.
6. Shubair M., Stanek R., White S., Larsen B. Effects of chlorhexidine gluconate douche on normal vaginal flora. Gynecol Obstet Invest 1992, 34:229-233.
7. Stray-Pedersen B., Bergan T., Hafstad A., Normann E., Grogaard J., Vangdal M. Vaginal disinfection with chlorhexidine during childbirth. Int J Antimicrob Agents 1999, 12:245-251.
8. Rosin M., Welk A., Kocher T., Majic-Todt A., Kramer A., Pitten F.A. The effect of a polyhexamethylene biguanide mouth rinse compared to an essential oil rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque regrowth. J Clin Periodontol 2002, 29:392-399.
9. Patton D.L., Sweeney Y.T., McKay T.L., DeMers S.M., Clark A.M., Rabe L.K., et al. 0.25% chlorhexidine gluconate gel. A protective topical microbicide. Sex Transm Dis 1998, 25:421-424.
10. Keeven J., Wrobel S., Portoles M., DeCicco B.T. Evaluating the preservative effectiveness of RGP lens care solutions. Clao J 1995, 21:238-241.
11. Larkin D.F., Kilvington S., Dart J.K. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology 1992, 99:185-191.
12. Rosin M., Welk A., Bernhardt O., Ruhnau M., Pitten F.A., Kocher T., et al. Effect of a polyhexamethylene biguanide mouth rinse on bacterial counts and plaque. J Clin Periodontol 2001, 28:1121-1126.
13. Millis N.F., Eager E., Hay A.J., Kasian P.A., Pickering W.J., Tan M.A. Survey of bacteria in private swimming pools. Med J Aust 1981, 1:573-575.
14. Gerli S., Rossetti D., Di Renzo G.C. A new approach for the treatment of bacterial vaginosis: use of polyhexamethylene biguanide. A prospective, randomized study. Eur Rev Med Pharmacol Sci 2003, 7:127-130.
15. Valluri S., Fleming T.P., Laycock K.A., Tarle I.S., Goldberg M.A., Garcia-Ferrer F.J., et al. In vitro and in vivo effects of polyhexamethylene biguanide against herpes simplex virus infection. Cornea 1997, 16:556-559.
16. Krebs F.C., Miller S.R., Ferguson M.L., Labib M., Rando R.F., Wigdahl B. Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed Pharmacother 2005, 59:438-445.
17. East G.C., McIntyre J.E., Shao J. Polybiguanides: synthesis and characterization of polybiguanides containing hexamethylene groups. Polymer 1997, 38:3973-3984.
18. Zhang Y., Jiang J., Chen Y. Synthesis and antimicrobial activity of polymeric guanidine and biguanidine salts. Polymer 1999, 40:6189-6198.
19. Charneau P., Mirambeau G., Roux P., Paulous S., Buc H., Clavel F. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994, 241:651-662.
20. Krebs F.C., Miller S.R., Malamud D., Howett M.K., Wigdahl B. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res 1999, 43:157-173.
21. Catalone B.J., Kish-Catalone T.M., Budgeon L.R., Neely E.B., Ferguson M., Krebs F.C., et al. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 2004, 48:1837-1847.
22. Catalone B.J., Miller S.R., Ferguson M.L., Malamud D., Kish-Catalone T., Thakkar N.J., et al. Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. Biomed Pharmacother 2005, 59:430-437.
23. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971-977.
24. Krebs F.C., Miller S.R., Catalone B.J., Welsh P.A., Malamud D., Howett M.K., et al. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes. Antimicrob Agents Chemother 2000, 44:1954-1960.
25. Broxton P., Woodcock P.M., Heatley F., Gilbert P. Interaction of some polyhexamethylene biguanides and membrane phospholipids in Escherichia coli. J Appl Bacteriol 1984, 57:115-124.
26. Ikeda T., Ledwith A., Bamford C.H., Hann R.A. Interaction of a polymeric biguanide biocide with phospholipid membranes. Biochim Biophys Acta 1984, 769:57-66.
27. Thakkar N., Pirrone V., Passic S., Zhu W., Kholodovych V., Welsh W., et al. Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 2009, 53:631-638.
28. Thakkar N., Pirrone V., Passic S., Keogan S., Zhu W., Kholodovych V., et al. Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 2010, 54:1965-1972.
29. Altenburg J.D., Broxmeyer H.E., Jin Q., Cooper S., Basu S., Alkhatib G. A naturally occurring splice variant of CXCL12/stromal cell-derived factor 1 is a potent human immunodeficiency virus type 1 inhibitor with weak chemotaxis and cell survival activities. J Virol 2007, 81:8140-8148.
30. Dettin M., Pasquato A., Scarinci C., Zanchetta M., De Rossi A., Di Bello C. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1. J Med Chem 2004, 47:3058-3064.
31. Proudfoot A.E., Fritchley S., Borlat F., Shaw J.P., Vilbois F., Zwahlen C., et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001, 276:10620-10626.